Low-dose metronomic chemotherapy: From past experience to new paradigms in the treatment of cancer

Drug Discovery Today

Volumn 18, Issue 3-4, 2013, Pages 193-201

  Loven, David ^a   Hasnis, Erez ^b,c   Bertolini, Francesco ^d   Shaked, Yuval ^b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Rambam Health Care Campus ^*  (Israel)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LETROZOLE; METHOTREXATE; NAVELBINE;

BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CELL TYPE; COLORECTAL CARCINOMA; DRUG TOLERABILITY; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; METRONOMIC DRUG ADMINISTRATION; OVARY CARCINOMA; PROSTATE CARCINOMA; REVIEW; TUMOR MICROENVIRONMENT;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNE SYSTEM; NEOPLASMS;

EID: 84873086527     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.07.015     Document Type: Review

References (74)

1. G.L. Klement, and B.A. Kamen Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? J. Pediatr. Hematol. Oncol. 33 2011 1 3
2. T. Browder Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res. 60 2000 1878 1886
3. G. Klement Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J. Clin. Invest. 105 2000 R15 R24
4. E. Pasquier Metronomic chemotherapy: new rationale for new directions Nat. Rev. Clin. Oncol. 7 2010 455 465
5. D. Hanahan Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice J. Clin. Invest. 105 2000 1045 1047
6. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat. Rev. Cancer 4 2004 423 436
7. G. Bocci Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs Cancer Res. 62 2002 6938 6943
8. G. Bocci Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy Proc. Natl. Acad. Sci. U. S. A. 100 2003 12917 12922
9. D. Loven Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients Acta Oncol. 47 2008 104 109
10. M. Colleoni Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects Ann. Oncol. 17 2006 232 238
11. Y. Shaked Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity Blood 106 2005 3058 3061
12. F. Bertolini Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells Cancer Res. 63 2003 4342 4346
13. J.H. Burton Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma J. Vet. Intern. Med. 25 2011 920 926
14. C. Banissi Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model Cancer Immunol. Immunother. 58 2009 1627 1634
15. S. Wan Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells PLoS One 7 2012 E32542
16. J.C. Doloff, and D.J. Waxman VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression Cancer Res. 72 2012 1103 1115
17. V.R. Rozados The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide Oncol. Res. 18 2010 601 605
18. R. Kaneno Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations J. Transl. Med. 7 2009 58
19. Y. Ge Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome Cancer Immunol. Immunother. 61 2012 353 362
20. J. Qiao Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus Clin. Cancer Res. 14 2008 259 269
21. C.K. Ingemarsdotter Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer Oncogene 29 2010 6051 6063
22. T.A. Cheema Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts Clin. Cancer Res. 17 2011 7383 7393
23. M. Onimaru Combination with low-dose gemcitabine and hTERT-promoter- dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer Cancer Lett. 294 2010 178 186
24. F. Tas Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer Cancer Chemother. Pharmacol. 61 2008 721 725
25. Y. Shaked Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents Cancer Cell 14 2008 263 273
26. S. Gingis-Velitski Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice Cancer Res. 71 2011 6986 6996
27. L.G. Daenen Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells Cancer Res. 71 2011 6976 6985
28. Y. Shaked Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents Cancer Res. 69 2009 7524 7528
29. J.M. Ebos Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy Proc. Natl. Acad. Sci. U. S. A. 104 2007 17069 17074
30. L.G. Daenen Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models Mol. Cancer Ther. 8 2009 2872 2881
31. K. Pietras, and D. Hanahan A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J. Clin. Oncol. 23 2005 939 952
32. Y. Shaked Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy Cancer Res. 65 2005 7045 7051
33. T.E. Hutson, and R.A. Figlin Evolving role of novel targeted agents in renal cell carcinoma Oncology (Williston Park) 21 2007 1175 1180 (discussion 1184, 1187, 1190)
34. W.M. Merritt Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer Mol. Cancer Ther. 9 2010 985 995
35. K. Hashimoto Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer Mol. Cancer Ther. 9 2010 996 1006
36. T. Reya Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
37. A. Viale Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells Nature 457 2009 51 56
38. C. Calabrese A perivascular niche for brain tumor stem cells Cancer Cell 11 2007 69 82
39. B. Beck A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours Nature 478 2011 399 403
40. C. Folkins Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors Cancer Res. 67 2007 3560 3564
41. I. Martin-Padura Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts Lab. Invest. 92 2012 952 966
42. M.C. Le Deley Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial J. Clin. Oncol. 28 2010 3987 3993
43. T. Lam From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials Anticancer Drugs 17 2006 113 121
44. M. Colleoni Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann. Oncol. 13 2002 73 80
45. T. Nelius Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature Cancer Treat. Rev. 37 2011 444 455
46. A.A. Garcia Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J. Clin. Oncol. 26 2008 76 82
47. A. Sanchez-Munoz Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer Oncology 79 2010 98 104
48. Y. Ogata Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence J. Exp. Clin. Cancer Res. 26 2007 475 482
49. R. Scalamogna UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen Oncology 72 2007 267 273
50. Y.M. Chen A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy J. Thorac. Oncol. 6 2011 1110 1116
51. S. He Capecitabine 'metronomic' chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy Med. Oncol. 29 2012 100 106
52. T. Ishikawa Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma World J. Gastroenterol. 14 2008 2797 2801
53. A. Berruti Metronomic therapy concepts in the management of adrenocortical carcinoma Horm. Cancer 2 2011 378 384
54. H. Wong, and T. Yau Review: metronomic chemotherapy for advanced cutaneous angiosarcoma Clin. Adv. Hematol. Oncol. 9 2011 504 506
55. F. Stockhammer Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma J. Neurooncol. 100 2010 407 415
56. N. Andre Pilot study of a pediatric metronomic 4-drug regimen Oncotarget 2 2011 960 965
57. M.W. Kieran A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer J. Pediatr. Hematol. Oncol. 27 2005 573 581
58. P. Fedele Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer Eur. J. Cancer 48 2012 24 29
59. U. Emmenegger Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide Neoplasia 13 2011 40 48
60. L. Orlando Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer BMC Cancer 6 2006 225
61. R. Addeo Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer Clin. Breast Cancer 10 2010 301 306
62. A. Fontana Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer Clin. Cancer Res. 15 2009 4954 4962
63. S. Ladoire Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure Anticancer Res. 30 2010 4317 4323
64. V. Gebbia Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel Urology 78 2011 1125 1130
65. R.A. Burger Experience with bevacizumab in the management of epithelial ovarian cancer J. Clin. Oncol. 25 2007 2902 2908
66. G. Allegrini Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers Angiogenesis 15 2012 275 286
67. E. Pasquier Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment Oncotarget 2 2011 797 809
68. V. Gebbia Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma Anticancer Res. 32 2012 529 536
69. T. Yamashita Clinical usefulness of oral combination chemotherapy of 5′-deoxy-5-fluorouridine (5′-DFUR) and cyclophosphamide for metastatic breast cancer Breast Cancer 13 2006 334 339
70. Z. Wang An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study Cancer Chemother. Pharmacol. 69 2012 515 522
71. N.S. Wong Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response J. Clin. Oncol. 28 2010 723 730
72. A. Bottini Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients J. Clin. Oncol. 24 2006 3623 3628
73. S. Dellapasqua Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer J. Clin. Oncol. 26 2008 4899 4905
74. E. Montagna Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity Clin. Breast Cancer 12 2012 207 214